IBB Performance — iShares Biotechnology ETF
Data updated: 2026-08-25
IBB returned +12.73% year to date and +50.60% over one year to Jun 2026. Annualised returns are +14.72% over 3 years and +3.31% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $151, against $138 for the category, and to $151 over one year, against $137. Volatility over the past three years was 17.77% a year. In the 12 months to Jun 2026 the fund took in a net $1.0B, and assets reached $9.09B.
IBB Growth of $100
What $100 invested in iShares Biotechnology ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | IBB | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $151 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $151 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $118 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $177 | $182 |
IBB Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +12.73% |
| 1 year | +50.60% |
| 3 years (annualised) | +14.72% |
| 5 years (annualised) | +3.31% |
IBB Annual Returns
Calendar-year total returns of iShares Biotechnology ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +12.73% |
| 2025 | +28.04% |
| 2024 | −2.40% |
| 2023 | +3.62% |
| 2022 | −13.59% |
| 2021 | +0.97% |
| 2020 | +25.89% |
| 2019 (Jul–Dec) | +10.65% |
IBB Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.1% | +1.7% | −3.6% | −0.1% | +2.1% | +10.3% | — | — | — | — | — | — |
| 2025 | +4.9% | −1.2% | −6.6% | −0.9% | −3.9% | +3.9% | +4.9% | +4.1% | +4.5% | +10.4% | +8.9% | −2.7% |
| 2024 | −1.0% | +1.9% | +0.4% | −7.6% | +5.4% | +2.6% | +7.7% | +0.3% | −1.6% | −3.6% | +0.9% | −6.6% |
| 2023 | +3.9% | −6.7% | +1.6% | +1.0% | −3.2% | +0.5% | +1.8% | −0.4% | −4.9% | −7.0% | +6.4% | +12.4% |
| 2022 | −13.5% | −4.4% | +3.3% | −10.4% | 0.0% | +0.9% | +5.3% | −2.1% | −3.4% | +9.9% | +6.0% | −3.6% |
| 2021 | +6.2% | −2.3% | −4.2% | +2.9% | −2.0% | +7.9% | +1.3% | +4.0% | −6.2% | −1.2% | −3.4% | −1.0% |
| 2020 | −5.6% | +0.3% | −5.4% | +15.0% | +8.5% | +1.6% | −1.7% | +0.9% | −0.1% | −3.8% | +11.2% | +4.5% |
| 2019 | — | — | — | — | — | — | −3.1% | −2.6% | −3.2% | +7.7% | +11.5% | +0.9% |
IBB Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 17.77%
- 3-year Sharpe ratio: 0.58 (vs 4.5% risk-free rate)
- Best month: +12.40% (Dec 2023)
- Worst month: −7.57% (Apr 2024)
IBB Fund Flows
Monthly money in and out of iShares Biotechnology ETF, from SEC Form N-PORT.
- 12-month net flow: $1.0B
- 12-month gross sales (incl. reinvestments): $11.7B
- Sales ÷ redemptions: 1.10×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $984.1M | $684.8M | $299.2M |
| May 2026 | $791.0M | $966.2M | −$175.2M |
| Apr 2026 | $741.5M | $908.2M | −$166.7M |
| Mar 2026 | $942.1M | $1.3B | −$332.0M |
| Feb 2026 | $1.2B | $1.1B | $102.1M |
| Jan 2026 | $829.2M | $807.8M | $21.3M |
| Dec 2025 | $936.7M | $1.1B | −$209.1M |
| Nov 2025 | $2.6B | $1.0B | $1.6B |
| Oct 2025 | $871.4M | $861.3M | $10.2M |
| Sep 2025 | $872.8M | $721.9M | $150.9M |
| Aug 2025 | $566.5M | $637.8M | −$71.3M |
| Jul 2025 | $335.0M | $480.9M | −$146.0M |
IBB Assets Under Management
Net assets of iShares Biotechnology ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $9.09B |
| 2026-03-31 | $8.12B |
| 2025-12-31 | $8.34B |
| 2025-09-30 | $5.94B |
| 2025-06-30 | $5.28B |
| 2025-03-31 | $5.81B |
| 2024-12-31 | $6.46B |
| 2024-09-30 | $7.56B |
| 2024-06-30 | $7.36B |
| 2024-03-31 | $7.63B |
| 2023-12-31 | $7.46B |
| 2023-09-30 | $6.98B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.